Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV

摘要: Chronic infection with hepatitis C virus (HCV) is a major public health problem, nearly 170 million infected individuals worldwide. Current treatment for chronic combination of pegylated IFN-α2 and ribavirin (RBV); however, this effective in fewer than 50% patients HCV genotype 1 or 4. Recent studies identified the chemokine CXCL10 (also known as IP-10) an important negative prognostic biomarker. Given that mediates chemoattraction activated lymphocytes, it counterintuitive correlates therapeutic nonresponsiveness. Herein, we offer new insight into paradox provide evidence plasma chronically exists antagonist form, due to situ amino-terminal truncation protein. We further demonstrated dipeptidyl peptidase IV (DPP4; also CD26), possibly other proteases, generation form(s) CXCL10. These data what believe be first antagonism human disease identify possible factor contributing inability clear HCV.